The global inhalation anesthetics market size was estimated to be USD 2.08 billion in 2023 and is expected to reach at USD 5.55 billion by 2034 with a CAGR of 9.34% during the forecast period 2024-2034. Increasing government funding for research & development of innovative inhalation anesthetics, growing prevalence of chronic disorders such as cancer, respiratory diseases, & gastrointestinal disorders, surge in number of surgical procedures performed for disease treatment & development, rising acquisitions within market players, increasing demand for lesser duration of hospital stays, growing innovations in inhalation devices, and surge in launch of novel inhalation anesthetic drugs are some of the key factors boosting the market growth.
Surge in launch of novel inhalation anesthetic drugs is predicted to boost the market growth during the forecast period. Compared to intravenous anesthesia, inhalation anesthesia improves patient outcomes. Anesthetics can be administered safely through the respiratory system, enabling manageable and efficient sedation. Hence, Inhalation anesthesia has more patient advantages than intravenous anesthesia. For instance, in February 2022, Sedana Medical AB has introduced Sedaconda (isoflurane) in Germany. The European DCP approval for Sedaconda was granted in July 2021, and it has also received official authorization in 14 different countries. In the same year, further requests for marketing approval were submitted. For 2022, Sedana Medical anticipates obtaining national approvals for Sedaconda in Italy, Poland, Switzerland, and the United Kingdom.
By drug, sevoflurane was the highest revenue-grossing segment in the global inhalation anesthetics market in 2023 owing to increasing adoption of inhalation anesthetic, rising mergers & acquisitions within market players, and growing research & development activities. For instance, in February 2022, According to a statement released by the International Institute for Integrative Sleep Medicine, scientists from the University of Tsukuba explored the impact of the general anesthetic sevoflurane and found that it has the potential to ameliorate changes in sleep caused by inflammation. Additionally, isoflurane is predicted to grow at fastest CAGR during the forecast period owing to the rising preference of isoflurane for inhalation general anesthesia by anesthesiologists and surge in approvals by regulatory bodies.
By application, maintenance was the highest revenue-grossing segment in the global inhalation anesthetics market in 2023 owing to the growing preference for inhaled anesthetics for maintaining anesthesia and rising introduction of strict guidelines. For instance, in June 2022, In response to growing apprehensions about curtailing the impact of greenhouse gases, the American Society of Anesthesiologists has issued directives. These guidelines aim to decrease the utilization of inhalation anesthesia, which could potentially have a negative influence on market expansion. Additionally, induction is predicted to grow at fastest CAGR during the forecast period owing to the factors influencing induction of anesthesia include Minimum Alveolar Concentration (MAC), a therapeutic index of the medicine, age of the patient, blood/gas solubility, rate of metabolism by kidney/liver, and compatibility with other medications.
By end-user, hospitals was the highest revenue-grossing segment in the global inhalation anesthetics market in 2023 owing to the growing number of surgeries performed in hospitals, surge in number of an anesthesiologist, presence of better patient monitoring services for management, and increasing launch of advanced products. For instance, in August 2022, Piramal Critical Care has introduced the initial Generic Zinc Sulfate Injection in the U.S. market. This product has gained approval from the U.S. Food and Drug Administration and holds the Competitive Generic Therapy (CGT) designation. This designation is intended to increase market competitiveness for drugs that are the exclusive source. Additionally, ambulatory surgical centers is predicted to grow at fastest CAHR during the forecast period owing to a competitive advantage in the setting of an ambulatory surgical facility and a specialized context where same-day procedures are performed, necessitating inhalation anesthetics with quick effects & quick recovery times.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising government funding for research & development of innovative inhalation anesthetics, increasing prevalence of cancer, growing number of surgical procedures performed for disease treatment and development, and surge in acquisitions within market players. For instance, in January 2022, Dechra Pharmaceuticals has revealed its purchase of Isoflurane USP Inhalant Anesthetic and Sevoflurane USP Inhalant Anesthetic from Halocarbon Life Sciences. These two inhalant anesthesia solutions find applications in both human and veterinary medicine. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the surge in number of surgical procedures, growing geriatric population, increasing demand for sevoflurane & desflurane for day surgeries, and rising launch of innovative products. For instance, in April 2022, The FDA has granted approval to the initial software designed to partially automate the administration of anesthesia during surgical procedures. End-tidal (Et) Control is a software that collaborates with GE's Aisys CS2 Anesthesia Delivery System, allowing anesthesiologists to establish predefined end-tidal oxygen and anaesthetic drug concentrations. Once these levels are configured, the system can adapt to achieve and sustain the specified targets throughout the surgery.
Surge in launch of novel inhalation anesthetic drugs is predicted to boost the market growth during the forecast period. Compared to intravenous anesthesia, inhalation anesthesia improves patient outcomes. Anesthetics can be administered safely through the respiratory system, enabling manageable and efficient sedation. Hence, Inhalation anesthesia has more patient advantages than intravenous anesthesia. For instance, in February 2022, Sedana Medical AB has introduced Sedaconda (isoflurane) in Germany. The European DCP approval for Sedaconda was granted in July 2021, and it has also received official authorization in 14 different countries. In the same year, further requests for marketing approval were submitted. For 2022, Sedana Medical anticipates obtaining national approvals for Sedaconda in Italy, Poland, Switzerland, and the United Kingdom.
By drug, sevoflurane was the highest revenue-grossing segment in the global inhalation anesthetics market in 2023 owing to increasing adoption of inhalation anesthetic, rising mergers & acquisitions within market players, and growing research & development activities. For instance, in February 2022, According to a statement released by the International Institute for Integrative Sleep Medicine, scientists from the University of Tsukuba explored the impact of the general anesthetic sevoflurane and found that it has the potential to ameliorate changes in sleep caused by inflammation. Additionally, isoflurane is predicted to grow at fastest CAGR during the forecast period owing to the rising preference of isoflurane for inhalation general anesthesia by anesthesiologists and surge in approvals by regulatory bodies.
By application, maintenance was the highest revenue-grossing segment in the global inhalation anesthetics market in 2023 owing to the growing preference for inhaled anesthetics for maintaining anesthesia and rising introduction of strict guidelines. For instance, in June 2022, In response to growing apprehensions about curtailing the impact of greenhouse gases, the American Society of Anesthesiologists has issued directives. These guidelines aim to decrease the utilization of inhalation anesthesia, which could potentially have a negative influence on market expansion. Additionally, induction is predicted to grow at fastest CAGR during the forecast period owing to the factors influencing induction of anesthesia include Minimum Alveolar Concentration (MAC), a therapeutic index of the medicine, age of the patient, blood/gas solubility, rate of metabolism by kidney/liver, and compatibility with other medications.
By end-user, hospitals was the highest revenue-grossing segment in the global inhalation anesthetics market in 2023 owing to the growing number of surgeries performed in hospitals, surge in number of an anesthesiologist, presence of better patient monitoring services for management, and increasing launch of advanced products. For instance, in August 2022, Piramal Critical Care has introduced the initial Generic Zinc Sulfate Injection in the U.S. market. This product has gained approval from the U.S. Food and Drug Administration and holds the Competitive Generic Therapy (CGT) designation. This designation is intended to increase market competitiveness for drugs that are the exclusive source. Additionally, ambulatory surgical centers is predicted to grow at fastest CAHR during the forecast period owing to a competitive advantage in the setting of an ambulatory surgical facility and a specialized context where same-day procedures are performed, necessitating inhalation anesthetics with quick effects & quick recovery times.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising government funding for research & development of innovative inhalation anesthetics, increasing prevalence of cancer, growing number of surgical procedures performed for disease treatment and development, and surge in acquisitions within market players. For instance, in January 2022, Dechra Pharmaceuticals has revealed its purchase of Isoflurane USP Inhalant Anesthetic and Sevoflurane USP Inhalant Anesthetic from Halocarbon Life Sciences. These two inhalant anesthesia solutions find applications in both human and veterinary medicine. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the surge in number of surgical procedures, growing geriatric population, increasing demand for sevoflurane & desflurane for day surgeries, and rising launch of innovative products. For instance, in April 2022, The FDA has granted approval to the initial software designed to partially automate the administration of anesthesia during surgical procedures. End-tidal (Et) Control is a software that collaborates with GE's Aisys CS2 Anesthesia Delivery System, allowing anesthesiologists to establish predefined end-tidal oxygen and anaesthetic drug concentrations. Once these levels are configured, the system can adapt to achieve and sustain the specified targets throughout the surgery.
Segmentation: Inhalation Anesthetics Market Report 2022 - 2033
Inhalation Anesthetics Market Analysis & Forecast by Drug 2023 - 2034 (Revenue USD Bn)
- Desflurane
- Sevoflurane
- Isoflurane
- Others
Inhalation Anesthetics Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Maintenance
- Induction
Inhalation Anesthetics Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Ambulatory Surgical Centres
- Hospitals
- Others
Inhalation Anesthetics Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Inhalation Anesthetics Market: Drug Estimates & Trend Analysis
8. Inhalation Anesthetics Market: Application Estimates & Trend Analysis
9. Inhalation Anesthetics Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Inhalation Anesthetics Market
12. Europe Global Inhalation Anesthetics Market
13. Asia Pacific Global Inhalation Anesthetics Market
14. Latin America Global Inhalation Anesthetics Market
15. MEA Global Inhalation Anesthetics Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Jiangsu Hengrui Medicine Co. Ltd
- Lunan Pharmaceutical Group Co. Ltd
- Piramal Enterprises Limited
- AbbVie Inc.
- Fresenius Kabi AG (Fresenius SE& Co. KGaA)
- Merck KGaA
- Troikaa Pharmaceuticals Ltd
- Baxter International Inc.
- Hikma Pharmaceuticals PLC
- Dechra Pharmaceuticals PLC (Halocarbon Life Sciences LLC)
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | October 2023 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 2.08 Billion |
| Forecasted Market Value ( USD | $ 5.55 Billion |
| Compound Annual Growth Rate | 9.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
